nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—PDE3B—polycystic ovary syndrome	0.677	1	CbGaD
Dipyridamole—PDE5A—clitoris—polycystic ovary syndrome	0.0159	0.152	CbGeAlD
Dipyridamole—Abdominal distress—Metformin—polycystic ovary syndrome	0.0118	0.207	CcSEcCtD
Dipyridamole—Emotional distress—Metformin—polycystic ovary syndrome	0.00376	0.0658	CcSEcCtD
Dipyridamole—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.00304	0.0532	CcSEcCtD
Dipyridamole—PDE6A—pituitary gland—polycystic ovary syndrome	0.00302	0.0289	CbGeAlD
Dipyridamole—Rigors—Metformin—polycystic ovary syndrome	0.00196	0.0343	CcSEcCtD
Dipyridamole—PRUNE—uterus—polycystic ovary syndrome	0.00195	0.0186	CbGeAlD
Dipyridamole—PRUNE—pituitary gland—polycystic ovary syndrome	0.00191	0.0183	CbGeAlD
Dipyridamole—PRUNE—adipose tissue—polycystic ovary syndrome	0.00191	0.0182	CbGeAlD
Dipyridamole—PDE1C—adrenal gland—polycystic ovary syndrome	0.00189	0.0181	CbGeAlD
Dipyridamole—PDE6D—uterus—polycystic ovary syndrome	0.00188	0.018	CbGeAlD
Dipyridamole—PDE6D—adipose tissue—polycystic ovary syndrome	0.00184	0.0176	CbGeAlD
Dipyridamole—PRUNE—adrenal gland—polycystic ovary syndrome	0.00171	0.0164	CbGeAlD
Dipyridamole—PDE6D—adrenal gland—polycystic ovary syndrome	0.00165	0.0158	CbGeAlD
Dipyridamole—PDE6B—adrenal gland—polycystic ovary syndrome	0.00162	0.0155	CbGeAlD
Dipyridamole—PRUNE—female gonad—polycystic ovary syndrome	0.00159	0.0152	CbGeAlD
Dipyridamole—PDE6D—female gonad—polycystic ovary syndrome	0.00154	0.0147	CbGeAlD
Dipyridamole—PDE6D—vagina—polycystic ovary syndrome	0.00153	0.0146	CbGeAlD
Dipyridamole—PDE11A—adrenal gland—polycystic ovary syndrome	0.00151	0.0144	CbGeAlD
Dipyridamole—PDE6B—vagina—polycystic ovary syndrome	0.0015	0.0144	CbGeAlD
Dipyridamole—PDE6G—adrenal gland—polycystic ovary syndrome	0.00145	0.0139	CbGeAlD
Dipyridamole—PDE2A—adrenal cortex—polycystic ovary syndrome	0.00136	0.013	CbGeAlD
Dipyridamole—Ear pain—Metformin—polycystic ovary syndrome	0.00136	0.0238	CcSEcCtD
Dipyridamole—PDE7B—adipose tissue—polycystic ovary syndrome	0.00131	0.0125	CbGeAlD
Dipyridamole—PDE11A—endocrine gland—polycystic ovary syndrome	0.00131	0.0125	CbGeAlD
Dipyridamole—PDE6H—endocrine gland—polycystic ovary syndrome	0.00131	0.0125	CbGeAlD
Dipyridamole—PDE7B—adrenal gland—polycystic ovary syndrome	0.00118	0.0113	CbGeAlD
Dipyridamole—PDE8A—adrenal cortex—polycystic ovary syndrome	0.00117	0.0112	CbGeAlD
Dipyridamole—PDE7A—endocrine gland—polycystic ovary syndrome	0.00117	0.0112	CbGeAlD
Dipyridamole—Migraine—Metformin—polycystic ovary syndrome	0.00114	0.02	CcSEcCtD
Dipyridamole—PDE2A—uterus—polycystic ovary syndrome	0.00112	0.0107	CbGeAlD
Dipyridamole—PDE2A—pituitary gland—polycystic ovary syndrome	0.0011	0.0105	CbGeAlD
Dipyridamole—PDE10A—adipose tissue—polycystic ovary syndrome	0.00109	0.0105	CbGeAlD
Dipyridamole—PDE2A—adipose tissue—polycystic ovary syndrome	0.00109	0.0105	CbGeAlD
Dipyridamole—PDE1B—adipose tissue—polycystic ovary syndrome	0.00108	0.0104	CbGeAlD
Dipyridamole—PDE8B—uterus—polycystic ovary syndrome	0.00107	0.0102	CbGeAlD
Dipyridamole—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00106	0.0186	CcSEcCtD
Dipyridamole—Cramp muscle—Metformin—polycystic ovary syndrome	0.00104	0.0183	CcSEcCtD
Dipyridamole—PDE8B—adipose tissue—polycystic ovary syndrome	0.00104	0.00999	CbGeAlD
Dipyridamole—PDE8A—endometrium—polycystic ovary syndrome	0.00104	0.00997	CbGeAlD
Dipyridamole—PDE3B—pituitary gland—polycystic ovary syndrome	0.00102	0.0098	CbGeAlD
Dipyridamole—PDE3B—adipose tissue—polycystic ovary syndrome	0.00102	0.00976	CbGeAlD
Dipyridamole—PDE2A—adrenal gland—polycystic ovary syndrome	0.000982	0.00939	CbGeAlD
Dipyridamole—PDE10A—adrenal gland—polycystic ovary syndrome	0.000982	0.00939	CbGeAlD
Dipyridamole—Sweating increased—Metformin—polycystic ovary syndrome	0.000976	0.0171	CcSEcCtD
Dipyridamole—Angina pectoris—Metformin—polycystic ovary syndrome	0.000976	0.0171	CcSEcCtD
Dipyridamole—PDE1B—adrenal gland—polycystic ovary syndrome	0.000973	0.00931	CbGeAlD
Dipyridamole—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000961	0.0168	CcSEcCtD
Dipyridamole—PDE8A—uterus—polycystic ovary syndrome	0.00096	0.00919	CbGeAlD
Dipyridamole—PDE8A—pituitary gland—polycystic ovary syndrome	0.000943	0.00902	CbGeAlD
Dipyridamole—PDE8A—adipose tissue—polycystic ovary syndrome	0.000939	0.00899	CbGeAlD
Dipyridamole—PDE8B—adrenal gland—polycystic ovary syndrome	0.000936	0.00896	CbGeAlD
Dipyridamole—PDE1A—uterus—polycystic ovary syndrome	0.000929	0.00889	CbGeAlD
Dipyridamole—PDE10A—female gonad—polycystic ovary syndrome	0.000915	0.00876	CbGeAlD
Dipyridamole—PDE3B—adrenal gland—polycystic ovary syndrome	0.000915	0.00875	CbGeAlD
Dipyridamole—PDE2A—vagina—polycystic ovary syndrome	0.00091	0.00871	CbGeAlD
Dipyridamole—PDE1A—adipose tissue—polycystic ovary syndrome	0.000909	0.0087	CbGeAlD
Dipyridamole—PDE8B—vagina—polycystic ovary syndrome	0.000868	0.0083	CbGeAlD
Dipyridamole—PDE2A—endocrine gland—polycystic ovary syndrome	0.000851	0.00815	CbGeAlD
Dipyridamole—PDE1B—endocrine gland—polycystic ovary syndrome	0.000844	0.00807	CbGeAlD
Dipyridamole—PDE8A—adrenal gland—polycystic ovary syndrome	0.000842	0.00806	CbGeAlD
Dipyridamole—Bradycardia—Metformin—polycystic ovary syndrome	0.000817	0.0143	CcSEcCtD
Dipyridamole—PDE1A—adrenal gland—polycystic ovary syndrome	0.000815	0.0078	CbGeAlD
Dipyridamole—PDE8B—endocrine gland—polycystic ovary syndrome	0.000812	0.00777	CbGeAlD
Dipyridamole—Rhinitis—Metformin—polycystic ovary syndrome	0.000804	0.0141	CcSEcCtD
Dipyridamole—Hepatitis—Metformin—polycystic ovary syndrome	0.000802	0.0141	CcSEcCtD
Dipyridamole—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000798	0.014	CcSEcCtD
Dipyridamole—PDE3B—endocrine gland—polycystic ovary syndrome	0.000793	0.00759	CbGeAlD
Dipyridamole—PDE8A—female gonad—polycystic ovary syndrome	0.000785	0.00752	CbGeAlD
Dipyridamole—PDE8A—vagina—polycystic ovary syndrome	0.000781	0.00747	CbGeAlD
Dipyridamole—ADA—adipose tissue—polycystic ovary syndrome	0.000773	0.0074	CbGeAlD
Dipyridamole—PDE1A—female gonad—polycystic ovary syndrome	0.00076	0.00727	CbGeAlD
Dipyridamole—PDE4A—adipose tissue—polycystic ovary syndrome	0.000753	0.00721	CbGeAlD
Dipyridamole—Flushing—Metformin—polycystic ovary syndrome	0.000744	0.013	CcSEcCtD
Dipyridamole—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000744	0.013	CcSEcCtD
Dipyridamole—Angiopathy—Metformin—polycystic ovary syndrome	0.000728	0.0127	CcSEcCtD
Dipyridamole—Immune system disorder—Metformin—polycystic ovary syndrome	0.000725	0.0127	CcSEcCtD
Dipyridamole—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000723	0.0127	CcSEcCtD
Dipyridamole—Chills—Metformin—polycystic ovary syndrome	0.00072	0.0126	CcSEcCtD
Dipyridamole—PDE1A—endocrine gland—polycystic ovary syndrome	0.000707	0.00677	CbGeAlD
Dipyridamole—ADA—adrenal gland—polycystic ovary syndrome	0.000693	0.00663	CbGeAlD
Dipyridamole—Flatulence—Metformin—polycystic ovary syndrome	0.000688	0.0121	CcSEcCtD
Dipyridamole—Dysgeusia—Metformin—polycystic ovary syndrome	0.000684	0.012	CcSEcCtD
Dipyridamole—PDE4A—adrenal gland—polycystic ovary syndrome	0.000676	0.00646	CbGeAlD
Dipyridamole—Muscle spasms—Metformin—polycystic ovary syndrome	0.000671	0.0118	CcSEcCtD
Dipyridamole—SLC29A1—adrenal cortex—polycystic ovary syndrome	0.000668	0.00639	CbGeAlD
Dipyridamole—Tremor—Metformin—polycystic ovary syndrome	0.000654	0.0115	CcSEcCtD
Dipyridamole—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000648	0.0113	CcSEcCtD
Dipyridamole—ADA—vagina—polycystic ovary syndrome	0.000642	0.00615	CbGeAlD
Dipyridamole—PDE5A—adipose tissue—polycystic ovary syndrome	0.00064	0.00613	CbGeAlD
Dipyridamole—PDE4A—female gonad—polycystic ovary syndrome	0.00063	0.00603	CbGeAlD
Dipyridamole—Malaise—Metformin—polycystic ovary syndrome	0.00063	0.011	CcSEcCtD
Dipyridamole—Syncope—Metformin—polycystic ovary syndrome	0.000626	0.011	CcSEcCtD
Dipyridamole—PDE3A—adipose tissue—polycystic ovary syndrome	0.000623	0.00596	CbGeAlD
Dipyridamole—Palpitations—Metformin—polycystic ovary syndrome	0.000617	0.0108	CcSEcCtD
Dipyridamole—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000614	0.0108	CcSEcCtD
Dipyridamole—Hypertension—Metformin—polycystic ovary syndrome	0.000603	0.0106	CcSEcCtD
Dipyridamole—ADA—endocrine gland—polycystic ovary syndrome	0.000601	0.00575	CbGeAlD
Dipyridamole—SLC29A1—endometrium—polycystic ovary syndrome	0.000597	0.00571	CbGeAlD
Dipyridamole—Chest pain—Metformin—polycystic ovary syndrome	0.000594	0.0104	CcSEcCtD
Dipyridamole—Myalgia—Metformin—polycystic ovary syndrome	0.000594	0.0104	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00059	0.0103	CcSEcCtD
Dipyridamole—ABCC5—pituitary gland—polycystic ovary syndrome	0.000588	0.00563	CbGeAlD
Dipyridamole—Discomfort—Metformin—polycystic ovary syndrome	0.000587	0.0103	CcSEcCtD
Dipyridamole—ABCC5—adipose tissue—polycystic ovary syndrome	0.000586	0.0056	CbGeAlD
Dipyridamole—PDE5A—adrenal gland—polycystic ovary syndrome	0.000574	0.0055	CbGeAlD
Dipyridamole—Oedema—Metformin—polycystic ovary syndrome	0.00057	0.00998	CcSEcCtD
Dipyridamole—Shock—Metformin—polycystic ovary syndrome	0.000561	0.00982	CcSEcCtD
Dipyridamole—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000559	0.00979	CcSEcCtD
Dipyridamole—PDE3A—adrenal gland—polycystic ovary syndrome	0.000559	0.00535	CbGeAlD
Dipyridamole—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000558	0.00977	CcSEcCtD
Dipyridamole—Skin disorder—Metformin—polycystic ovary syndrome	0.000554	0.0097	CcSEcCtD
Dipyridamole—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000551	0.00965	CcSEcCtD
Dipyridamole—SLC29A1—uterus—polycystic ovary syndrome	0.00055	0.00526	CbGeAlD
Dipyridamole—SLC29A1—pituitary gland—polycystic ovary syndrome	0.00054	0.00517	CbGeAlD
Dipyridamole—SLC29A1—adipose tissue—polycystic ovary syndrome	0.000538	0.00515	CbGeAlD
Dipyridamole—PDE5A—female gonad—polycystic ovary syndrome	0.000536	0.00513	CbGeAlD
Dipyridamole—Hypotension—Metformin—polycystic ovary syndrome	0.000533	0.00933	CcSEcCtD
Dipyridamole—PDE5A—vagina—polycystic ovary syndrome	0.000532	0.00509	CbGeAlD
Dipyridamole—ABCC5—adrenal gland—polycystic ovary syndrome	0.000525	0.00503	CbGeAlD
Dipyridamole—PDE3A—female gonad—polycystic ovary syndrome	0.000521	0.00499	CbGeAlD
Dipyridamole—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000519	0.0091	CcSEcCtD
Dipyridamole—Paraesthesia—Metformin—polycystic ovary syndrome	0.000512	0.00896	CcSEcCtD
Dipyridamole—Dyspnoea—Metformin—polycystic ovary syndrome	0.000508	0.0089	CcSEcCtD
Dipyridamole—Somnolence—Metformin—polycystic ovary syndrome	0.000507	0.00887	CcSEcCtD
Dipyridamole—Dyspepsia—Metformin—polycystic ovary syndrome	0.000502	0.00879	CcSEcCtD
Dipyridamole—PDE5A—endocrine gland—polycystic ovary syndrome	0.000498	0.00477	CbGeAlD
Dipyridamole—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000492	0.00862	CcSEcCtD
Dipyridamole—Fatigue—Metformin—polycystic ovary syndrome	0.000491	0.00861	CcSEcCtD
Dipyridamole—ABCC5—female gonad—polycystic ovary syndrome	0.00049	0.00469	CbGeAlD
Dipyridamole—ABCC5—vagina—polycystic ovary syndrome	0.000487	0.00466	CbGeAlD
Dipyridamole—PDE3A—endocrine gland—polycystic ovary syndrome	0.000485	0.00464	CbGeAlD
Dipyridamole—SLC29A1—adrenal gland—polycystic ovary syndrome	0.000482	0.00462	CbGeAlD
Dipyridamole—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00047	0.00823	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000466	0.00816	CcSEcCtD
Dipyridamole—Urticaria—Metformin—polycystic ovary syndrome	0.000453	0.00793	CcSEcCtD
Dipyridamole—Abdominal pain—Metformin—polycystic ovary syndrome	0.000451	0.00789	CcSEcCtD
Dipyridamole—SLC29A1—female gonad—polycystic ovary syndrome	0.00045	0.0043	CbGeAlD
Dipyridamole—SLC29A1—vagina—polycystic ovary syndrome	0.000447	0.00428	CbGeAlD
Dipyridamole—SLC29A1—endocrine gland—polycystic ovary syndrome	0.000418	0.004	CbGeAlD
Dipyridamole—ABCC4—uterus—polycystic ovary syndrome	0.000415	0.00397	CbGeAlD
Dipyridamole—Asthenia—Metformin—polycystic ovary syndrome	0.000409	0.00716	CcSEcCtD
Dipyridamole—ABCC4—adipose tissue—polycystic ovary syndrome	0.000406	0.00388	CbGeAlD
Dipyridamole—Pruritus—Metformin—polycystic ovary syndrome	0.000403	0.00706	CcSEcCtD
Dipyridamole—Diarrhoea—Metformin—polycystic ovary syndrome	0.00039	0.00683	CcSEcCtD
Dipyridamole—Dizziness—Metformin—polycystic ovary syndrome	0.000377	0.0066	CcSEcCtD
Dipyridamole—ABCC4—adrenal gland—polycystic ovary syndrome	0.000364	0.00348	CbGeAlD
Dipyridamole—Vomiting—Metformin—polycystic ovary syndrome	0.000362	0.00635	CcSEcCtD
Dipyridamole—Rash—Metformin—polycystic ovary syndrome	0.000359	0.00629	CcSEcCtD
Dipyridamole—Dermatitis—Metformin—polycystic ovary syndrome	0.000359	0.00629	CcSEcCtD
Dipyridamole—Headache—Metformin—polycystic ovary syndrome	0.000357	0.00625	CcSEcCtD
Dipyridamole—ABCC4—female gonad—polycystic ovary syndrome	0.00034	0.00325	CbGeAlD
Dipyridamole—Nausea—Metformin—polycystic ovary syndrome	0.000339	0.00593	CcSEcCtD
Dipyridamole—ABCC4—endocrine gland—polycystic ovary syndrome	0.000316	0.00302	CbGeAlD
Dipyridamole—ABCB1—embryo—polycystic ovary syndrome	0.000214	0.00205	CbGeAlD
Dipyridamole—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000176	0.00168	CbGeAlD
Dipyridamole—ABCB1—endometrium—polycystic ovary syndrome	0.000157	0.0015	CbGeAlD
Dipyridamole—ABCB1—uterus—polycystic ovary syndrome	0.000144	0.00138	CbGeAlD
Dipyridamole—ABCB1—pituitary gland—polycystic ovary syndrome	0.000142	0.00136	CbGeAlD
Dipyridamole—ABCB1—adipose tissue—polycystic ovary syndrome	0.000141	0.00135	CbGeAlD
Dipyridamole—ABCB1—adrenal gland—polycystic ovary syndrome	0.000127	0.00121	CbGeAlD
Dipyridamole—ABCB1—female gonad—polycystic ovary syndrome	0.000118	0.00113	CbGeAlD
Dipyridamole—ABCB1—vagina—polycystic ovary syndrome	0.000117	0.00112	CbGeAlD
Dipyridamole—ABCB1—endocrine gland—polycystic ovary syndrome	0.00011	0.00105	CbGeAlD
Dipyridamole—PDE7A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.04e-05	6.47e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.04e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.04e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ISYNA1—polycystic ovary syndrome	1.03e-05	6.41e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IRS1—polycystic ovary syndrome	1.03e-05	6.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.03e-05	6.39e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.03e-05	6.37e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.02e-05	6.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PGR—polycystic ovary syndrome	1.02e-05	6.33e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.02e-05	6.32e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—POMC—polycystic ovary syndrome	1.01e-05	6.24e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.01e-05	6.23e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—ADRB2—polycystic ovary syndrome	1e-05	6.22e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—SERPINE1—polycystic ovary syndrome	1e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—INS—polycystic ovary syndrome	1e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NGFR—polycystic ovary syndrome	1e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—VEGFA—polycystic ovary syndrome	9.94e-06	6.16e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—POMC—polycystic ovary syndrome	9.94e-06	6.16e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—POMC—polycystic ovary syndrome	9.93e-06	6.15e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by NGF—IL6—polycystic ovary syndrome	9.93e-06	6.15e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.92e-06	6.15e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.92e-06	6.15e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NCOR1—polycystic ovary syndrome	9.92e-06	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PRL—polycystic ovary syndrome	9.91e-06	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ATF1—polycystic ovary syndrome	9.91e-06	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—INS—polycystic ovary syndrome	9.88e-06	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CRP—polycystic ovary syndrome	9.87e-06	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IRS2—polycystic ovary syndrome	9.87e-06	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRG1—polycystic ovary syndrome	9.73e-06	6.03e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NGFR—polycystic ovary syndrome	9.72e-06	6.03e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IGF1—polycystic ovary syndrome	9.69e-06	6e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.69e-06	6e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.69e-06	6e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—POMC—polycystic ovary syndrome	9.68e-06	6e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT2—polycystic ovary syndrome	9.68e-06	6e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—POMC—polycystic ovary syndrome	9.66e-06	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.66e-06	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling by GPCR—IL6—polycystic ovary syndrome	9.65e-06	5.98e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling by GPCR—IL6—polycystic ovary syndrome	9.65e-06	5.98e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PRL—polycystic ovary syndrome	9.64e-06	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—INS—polycystic ovary syndrome	9.63e-06	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.62e-06	5.96e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MTHFR—polycystic ovary syndrome	9.58e-06	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MTHFR—polycystic ovary syndrome	9.58e-06	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—IL6—polycystic ovary syndrome	9.57e-06	5.93e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—IL6—polycystic ovary syndrome	9.57e-06	5.93e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IGF1—polycystic ovary syndrome	9.56e-06	5.92e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT2—polycystic ovary syndrome	9.55e-06	5.92e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.55e-06	5.92e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—GNAS—polycystic ovary syndrome	9.53e-06	5.91e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PLAT—polycystic ovary syndrome	9.5e-06	5.89e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—GHRL—polycystic ovary syndrome	9.5e-06	5.89e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—IL6—polycystic ovary syndrome	9.4e-06	5.82e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.4e-06	5.82e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IGF1—polycystic ovary syndrome	9.32e-06	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT2—polycystic ovary syndrome	9.31e-06	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—GNAS—polycystic ovary syndrome	9.31e-06	5.77e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.29e-06	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.2e-06	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.15e-06	5.67e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NGFR—polycystic ovary syndrome	9.14e-06	5.67e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.14e-06	5.67e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	9.12e-06	5.65e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IRS2—polycystic ovary syndrome	9.12e-06	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IRS2—polycystic ovary syndrome	9.12e-06	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—VEGFA—polycystic ovary syndrome	9.1e-06	5.64e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—POMC—polycystic ovary syndrome	9.08e-06	5.63e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—NCOR1—polycystic ovary syndrome	9.08e-06	5.63e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.08e-06	5.63e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PRL—polycystic ovary syndrome	9.06e-06	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ATF1—polycystic ovary syndrome	9.06e-06	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IRS2—polycystic ovary syndrome	9.03e-06	5.6e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CRP—polycystic ovary syndrome	9.03e-06	5.6e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PPARG—polycystic ovary syndrome	8.96e-06	5.55e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.87e-06	5.49e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.85e-06	5.48e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.84e-06	5.48e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—POMC—polycystic ovary syndrome	8.83e-06	5.47e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	8.8e-06	5.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	8.8e-06	5.45e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.79e-06	5.45e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—INS—polycystic ovary syndrome	8.78e-06	5.44e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MTHFR—polycystic ovary syndrome	8.76e-06	5.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.73e-06	5.41e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—GNAS—polycystic ovary syndrome	8.71e-06	5.4e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRG1—polycystic ovary syndrome	8.7e-06	5.39e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IRS1—polycystic ovary syndrome	8.62e-06	5.34e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—CYP1A1—polycystic ovary syndrome	8.61e-06	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—IL6—polycystic ovary syndrome	8.6e-06	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.6e-06	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—GNAS—polycystic ovary syndrome	8.48e-06	5.25e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NGFR—polycystic ovary syndrome	8.36e-06	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IRS2—polycystic ovary syndrome	8.34e-06	5.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—POMC—polycystic ovary syndrome	8.31e-06	5.15e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.3e-06	5.14e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PRL—polycystic ovary syndrome	8.29e-06	5.13e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.24e-06	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.24e-06	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRG1—polycystic ovary syndrome	8.15e-06	5.05e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.08e-06	5e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.03e-06	4.98e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—MTHFR—polycystic ovary syndrome	8.02e-06	4.97e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.99e-06	4.95e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.99e-06	4.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.99e-06	4.95e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT2—polycystic ovary syndrome	7.98e-06	4.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.97e-06	4.94e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	7.96e-06	4.93e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IRS1—polycystic ovary syndrome	7.96e-06	4.93e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IRS1—polycystic ovary syndrome	7.96e-06	4.93e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.93e-06	4.91e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IRS1—polycystic ovary syndrome	7.88e-06	4.89e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.86e-06	4.87e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	7.84e-06	4.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—INS—polycystic ovary syndrome	7.62e-06	4.72e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—INS—polycystic ovary syndrome	7.62e-06	4.72e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.59e-06	4.7e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IRS2—polycystic ovary syndrome	7.45e-06	4.62e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.45e-06	4.62e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—IL6—polycystic ovary syndrome	7.41e-06	4.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	7.37e-06	4.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT2—polycystic ovary syndrome	7.37e-06	4.56e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT2—polycystic ovary syndrome	7.37e-06	4.56e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.34e-06	4.55e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT2—polycystic ovary syndrome	7.3e-06	4.52e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—LEP—polycystic ovary syndrome	7.29e-06	4.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—GNAS—polycystic ovary syndrome	7.29e-06	4.52e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	7.29e-06	4.52e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IRS1—polycystic ovary syndrome	7.28e-06	4.51e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.12e-06	4.41e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—SERPINE1—polycystic ovary syndrome	7e-06	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—SERPINE1—polycystic ovary syndrome	7e-06	4.34e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	6.99e-06	4.33e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.98e-06	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—INS—polycystic ovary syndrome	6.97e-06	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—BCL2—polycystic ovary syndrome	6.97e-06	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.94e-06	4.3e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—VEGFA—polycystic ovary syndrome	6.89e-06	4.27e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—LEP—polycystic ovary syndrome	6.83e-06	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.83e-06	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.83e-06	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRG1—polycystic ovary syndrome	6.82e-06	4.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.79e-06	4.21e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—IL6—polycystic ovary syndrome	6.77e-06	4.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT2—polycystic ovary syndrome	6.74e-06	4.17e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—IL6—polycystic ovary syndrome	6.7e-06	4.15e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—IL6—polycystic ovary syndrome	6.7e-06	4.15e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—STAR—polycystic ovary syndrome	6.67e-06	4.13e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	6.66e-06	4.13e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—LEP—polycystic ovary syndrome	6.64e-06	4.12e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IRS1—polycystic ovary syndrome	6.51e-06	4.03e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PPARG—polycystic ovary syndrome	6.51e-06	4.03e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—POMC—polycystic ovary syndrome	6.42e-06	3.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—SERPINE1—polycystic ovary syndrome	6.4e-06	3.97e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.38e-06	3.96e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—INS—polycystic ovary syndrome	6.38e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—BCL2—polycystic ovary syndrome	6.37e-06	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.33e-06	3.92e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—POMC—polycystic ovary syndrome	6.27e-06	3.88e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—IL6—polycystic ovary syndrome	6.25e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—LEP—polycystic ovary syndrome	6.25e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.24e-06	3.87e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—INS—polycystic ovary syndrome	6.23e-06	3.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—IL6—polycystic ovary syndrome	6.19e-06	3.84e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—IL6—polycystic ovary syndrome	6.17e-06	3.82e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IRS1—polycystic ovary syndrome	6.09e-06	3.78e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.08e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IGF1—polycystic ovary syndrome	6.03e-06	3.74e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT2—polycystic ovary syndrome	6.02e-06	3.73e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	5.96e-06	3.69e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	5.94e-06	3.68e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.93e-06	3.67e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—POMC—polycystic ovary syndrome	5.87e-06	3.64e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IRS2—polycystic ovary syndrome	5.84e-06	3.62e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—INS—polycystic ovary syndrome	5.83e-06	3.62e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.72e-06	3.55e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—LEP—polycystic ovary syndrome	5.71e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—POMC—polycystic ovary syndrome	5.71e-06	3.54e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—IL6—polycystic ovary syndrome	5.7e-06	3.53e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—IL6—polycystic ovary syndrome	5.7e-06	3.53e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—INS—polycystic ovary syndrome	5.68e-06	3.52e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	5.67e-06	3.51e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—IL6—polycystic ovary syndrome	5.66e-06	3.51e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IGF1—polycystic ovary syndrome	5.64e-06	3.5e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT2—polycystic ovary syndrome	5.64e-06	3.49e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	5.59e-06	3.47e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.57e-06	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—IL6—polycystic ovary syndrome	5.55e-06	3.44e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IGF1—polycystic ovary syndrome	5.49e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT2—polycystic ovary syndrome	5.49e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—POMC—polycystic ovary syndrome	5.37e-06	3.33e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.36e-06	3.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—INS—polycystic ovary syndrome	5.34e-06	3.31e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.21e-06	3.23e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LHB—polycystic ovary syndrome	5.17e-06	3.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IGF1—polycystic ovary syndrome	5.16e-06	3.2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT2—polycystic ovary syndrome	5.16e-06	3.2e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IRS1—polycystic ovary syndrome	5.1e-06	3.16e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—IL6—polycystic ovary syndrome	5.08e-06	3.15e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	5.05e-06	3.13e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—POMC—polycystic ovary syndrome	4.91e-06	3.04e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.9e-06	3.04e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	4.89e-06	3.03e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—INS—polycystic ovary syndrome	4.88e-06	3.02e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—polycystic ovary syndrome	4.72e-06	2.93e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—polycystic ovary syndrome	4.72e-06	2.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.72e-06	2.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.72e-06	2.92e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.61e-06	2.86e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	4.5e-06	2.79e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.48e-06	2.78e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—polycystic ovary syndrome	4.38e-06	2.71e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	4.36e-06	2.7e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—polycystic ovary syndrome	4.32e-06	2.68e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—polycystic ovary syndrome	4.32e-06	2.67e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—polycystic ovary syndrome	4.21e-06	2.61e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	4.2e-06	2.61e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—polycystic ovary syndrome	4.2e-06	2.6e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	4.04e-06	2.5e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	3.99e-06	2.47e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.95e-06	2.45e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.94e-06	2.44e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	3.77e-06	2.33e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	3.71e-06	2.3e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.69e-06	2.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.61e-06	2.24e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—polycystic ovary syndrome	3.61e-06	2.24e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.59e-06	2.22e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.37e-06	2.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—polycystic ovary syndrome	3.33e-06	2.06e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—polycystic ovary syndrome	3.33e-06	2.06e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—polycystic ovary syndrome	3.3e-06	2.04e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TH—polycystic ovary syndrome	3.21e-06	1.99e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	3.12e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.08e-06	1.91e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—polycystic ovary syndrome	3.05e-06	1.89e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.93e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—polycystic ovary syndrome	2.72e-06	1.69e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.62e-06	1.62e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—polycystic ovary syndrome	2.55e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.5e-06	1.55e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—polycystic ovary syndrome	2.48e-06	1.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.37e-06	1.47e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—polycystic ovary syndrome	2.33e-06	1.45e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.21e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.13e-06	1.32e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.79e-06	1.11e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.76e-06	1.09e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.75e-06	1.09e-05	CbGpPWpGaD
